LitAlert ~~

    • Genetic Risk of Second Primary Cancer in Breast Cancer Survivors: The Multiethnic Cohort Study.
    • Chen F, Park SL, Wilkens LR, Wan P, Hart SN, Hu C, Yadav SS, Couch FJ, Conti DV, de Smith AJ, Haiman CA.
    • Cancer Res. 2022 Jul 14:can.21.4461. doi: 10.1158/0008-5472.CAN-21-4461. Epub ahead of print.
    • Inherited Germline Cancer Susceptibility Gene Variants in Individuals with Non-Muscle-Invasive Bladder Cancer.
    • Pietzak EJ, Whiting K, Srinivasan P, Bandlamudi C, Khurram A, Joseph V, Walasek A, Bochner E, Clinton T, Almassi N, Truong H, de Jesus Escano MR, Wiseman M, Mandelker D, Kemel Y, Zhang L, Walsh MF, Cadoo KA, Coleman JA, Al-Ahmadie H, Rosenberg JE, Iyer GV, Solit DB, Ostrovnaya I, Offit K, Robson ME, Stadler ZK, Berger MF, Bajorin DF, Carlo M, Bochner BH.
    • Clin Cancer Res. 2022 Jul 14:ccr.22.1006. doi: 10.1158/1078-0432.CCR-22-1006. Epub ahead of print.
    • Double heterozygous pathogenic variants prevalence in a cohort of hereditary breast cancer patients.
    • Megid TB, Barros-Filho MC, Pisani JP, Achatz MI.
    • Front Oncol. 2022 Jul 14;12:873395. doi: 10.3389/fonc.2022.873395.
    • Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis.
    • Kar SP, Quiros PM, Gu M, Jiang T, Mitchell J, Langdon R, Iyer V, Barcena C, Vijayabaskar MS, Fabre MA, Carter P, Petrovski S, Burgess S, Vassiliou GS.
    • Nat Genet. 2022 Jul 14. doi: 10.1038/s41588-022-01121-z. Epub ahead of print.
    • Oncologists Seeing Lack of PARP Inhibitor Response in MSI-High, BRCA-Mutant Prostate Cancer Patients.
    • Kanski A.
    • Precision Oncology News. Biomarkers. BRCA. 2022 Jul 14.
    • Research news

    Original research:

    PARP Inhibitor Insensitivity to BRCA1/2 Monoallelic Mutations in Microsatellite Instability-High Cancers.